/
China SXT Pharmaceuticals, Inc. is a pharmaceutical company specializing in the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), including advanced, fine, and regular varieties under the historic 'Su Xuangtang' brand with nearly 280 years of heritage. Based in Taizhou, Jiangsu Province, China, the company blends ancient TCM traditions with modern production techniques, adhering to Good Manufacturing Practices (GMP) to ensure quality, safety, and efficacy in products like TCM granules tailored for hospitals and pharmacies. Established in 2005, it has pursued innovation through substantial R&D investments, including 13 invention patent applications and leadership from Chief Scientific Officer Dr. Jingzhen Deng, who drives strategies for non-decocting, advanced TCMP using aqueous extraction ratios, fingerprint analysis, and bioactive compound quantization. Key milestones include a 2019 strategic partnership with Zhangtai Group for product expansion, ongoing distribution network growth, and production enhancements to meet rising TCM demand. Operating primarily in China's domestic market via a Variable Interest Entity structure, China SXT Pharmaceuticals occupies a niche in the TCM sector, holding about 3% market share among competitors and capitalizing on increasing interest in alternative medicines. Its focus on rigorous quality control and modernization positions it within the evolving pharmaceutical landscape.
$2.45
$0.12 (-4.67%)
EOD Jul 17, 2026
The business is unprofitable at the operating level (-153.97% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 9.7% YoY. Margins deteriorated 23.5pp alongside, both lines moving the wrong way.
Negative free cash flow of -$2M. The business is consuming cash, not generating it. Operating margin contracted 23.5pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2M
▼ -9.7% YoY
Net Income (TTM)
-$3M
▼ -6.6% YoY
Op. Margin
-153.97%
▼ -23.5pp YoY
ROIC
-12.83%
▼ -1.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$2M
▼ -21.3% YoY
Op. Cash Flow (TTM)
-$2M
▼ -18.5% YoY
Net Debt
-$17M
Net Cash Position
Cash & Equiv.
$18M
3Y CAGR: -12.5%
Continue Research
China SXT Pharmaceuticals (SXTC)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, China SXT Pharmaceuticals scores 35/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
China SXT Pharmaceuticals scores 35 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -154.0% operating margin and a -12.8% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh SXTC's valuation and scores 35/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.